header logo image


Page 9«..891011..2030..»

Archive for the ‘Molecular Genetics’ Category

U of T researchers identify genes that enable cancer to evade the immune system – News@UofT

Saturday, September 26th, 2020

Researchers at the University of Toronto have mapped the genes that allow cancer cells to avoid being killed by the immune system a finding that paves the way for the development of immunotherapies that could be effective for large patient populations and across different tumour types.

Over the last decade, different forms of immunotherapy have emerged as really potent cancer treatments, but the reality is that they only generate durable responses in a fraction of patients and not for all tumour types, saysJason Moffat, a professor of molecular genetics at the Donnelly Centre for Cellular and Biomolecular Research who led the work.

The study, published inNature, also revealed the need for new therapy to take into account the genetic composition of tumours because of mutations in the cancer cells that can potentially make the disease worse in response to treatment, often referred to as cancer resistance mutations.

Its very important to understand at the molecular level how cancer develops resistance to immunotherapies in order to make them more broadly available, saysMoffat, who holds a Canada Research Chair in Functional Genomics of Cancer.Advances in systematic genetic approaches have let us key in on genes and molecular pathways that are commonly involved in resistance to therapy.

In immunotherapy, a patients own immune cells, known as T killer cells, are engineered to find and destroy cancer. But treatment resistance has precluded its use in most patients, especially those with solid tumours.

Its an ongoing battle between the immune system and cancer, where the immune system is trying to find and kill the cancer whereas the cancers job is to evade that killing, saysKeith Lawson, a co-lead author who iscompleting a PhD in Moffats lab as part of his medical training in the surgeon-scientist program at U of Ts Faculty of Medicine.

Tumour heterogeneity genetic variation in tumour cells within and across individuals that can impact therapy response further complicates treatment.

Its important to not just find genes that can regulate immune evasion in one model of cancer, but what you really want are to find those genes that you can manipulate in cancer cells across many models because those are going to make the best therapeutic targets, Lawson says.

The team, including collaborators from Agios Pharmaceuticals in Cambridge, Mass., looked for genes that regulate immune evasion across six genetically diverse tumor models derived from breast, colon, kidney and skin cancer. The cancer cells were placed in a dish alongside the T cells engineered to kill them, where the ensuing onslaught served as a baseline. The researchers next deployed the gene editing tool CRISPR to switch off one-by-one every gene in the cancer cells and measured the resulting deviations from the killing baseline.

They identified 182 core cancer intrinsic immune evasion genes whose deletion makes the cancer cells either more sensitive or more resistant to T cell attack. Among the resisters were all the genes known to develop mutations in patients who stopped responding to immunotherapy, giving the researchers confidence that their approach worked.

Many of the discovered genes had no previous links to immune evasion.

That was really exciting to see, because it means that our dataset was very rich in new biological information,Lawson says.

Genes involved in autophagy, a process when cells ramp up recycling their components to mitigate damage following stress, came up as key for immune evasion. This raises the possibility that cancers susceptibility to immunotherapy could be boosted by targeting its autophagy genes.

But as the researchers delved deeper, they found that deleting certain autophagy genes in pairs rendered the cells resistant to T cell killing. That means that if a tumour already harbours a mutation in one autophagy gene, a treatment that combines immunotherapy with a drug targeting another autophagy gene could make the disease worse in that patient.

We found this complete inversion of gene dependency,says Moffat. We did not anticipate this at all. What it shows us is that genetic context what mutations are present very much dictates whether the introduction of the second mutationwill cause no effect, resistance or sensitivity to therapy.

As more research explores combinatorial effects of mutations across different types of cancer cells, it should become possible to predict from a tumours DNA what type of therapy will be most effective.

The research was funded by the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research and Agios Pharmaceuticals.

Read more here:
U of T researchers identify genes that enable cancer to evade the immune system - News@UofT

Read More...

Bacterial viperins prove effective against human viruses: Researchers – Express Pharma

Saturday, September 26th, 2020

Virus-fighting viperins, part of the human immune system, turn out to have bacterial counterparts that might boost the fight against human disease.

By tracking the evolution of what may be our oldest means of fighting off viral infection, a group at the Weizmann Institute of Science has uncovered antiviral substances that may lead to the development of highly effective antiviral drugs. These substances are made by virus-fighting enzymes known as viperins, which were previously known to exist only in mammals, and have now been found in bacteria. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19. The study was published in Nature.

Studies conducted over the past decade by Prof Rotem Sorek and his group in the Institutes Molecular Genetics Department, as well as those by other scientists, have revealed that bacteria have highly sophisticated immune systems, despite their microscopic size. In particular, they are equipped to fight off phages viruses that infect bacteria. These differ from the kind that infect humans in their choice of targets, but they all consist of genetic material DNA or RNA that hijacks parts of the hosts replication machinery to make copies of themselves and spread.

Prof Sorek has found that some of these bacterial immune responses suggest evolutionary links to our own immune systems, and the present study in his lab shows the strongest evidence yet: They discovered that viperin antiviral enzymes whose function in the human immune system was understood only two years ago play a role in the immune system of bacteria.

In humans, viperin belongs to the innate immune system, the oldest part of the immune system in terms of evolution. It is produced when a signalling substance called interferon alerts the immune system to the presence of pathogenic viruses. The viperin then releases a special molecule that is able to act against a broad range of viruses with one simple rule: The molecule mimics nucleotides, bits of the genetic material needed to replicate their genomes. But the viperin molecule is fake: It is missing a vital piece that enables the next nucleotide in the growing strand to attach. Once the faux-nucleotide is inserted into the replicating viral genome, replication comes to a halt and the virus dies.

This simplicity and broad action against many different viruses suggested viperins had been around for some time, but could they go back as far as our common ancestors with bacteria? Led by former postdoctoral fellow Dr Aude Bernheim in Soreks lab, the group used techniques that had been developed in his lab to detect bacterial sequences encoding possible viperins. They then showed that these viperins did, indeed, protect bacteria against phage infection.

Whereas the human viperin produces a single kind of antiviral molecule, we found that the bacterial ones generate a surprising variety of molecules, each of which can potentially serve as a new antiviral drug, says Sorek.

Based on the genetic sequences, Sorek and his team were able to trace the evolutionary history of viperins: We found that this important component of our own antiviral immune system originated in the bacterial defence against viruses that infect them, says Sorek.

If the bacterial viperins prove effective against human viruses, Sorek thinks it may pave the way for the discovery of further molecules generated by bacterial immune systems that could be adopted as antiviral drugs for human diseases. As we did decades ago with antibiotics antibacterial substances that were first discovered in fungi and bacteria we might learn how to identify and adopt the antiviral strategies of organisms that have been fighting infection for hundreds of millions of years.

The current study was conducted in collaboration with researchers from Pantheon Biosciences, which has licensed the rights through Yeda Research and Development, the technology transfer arm of the Weizmann Institute of Science, to develop anti-viral drugs based on the findings. Further studies are underway to determine which of the bacterial viperins could be best adapted to fighting human viruses, including, COVID-19. Also participating in this research were Adi Millman, Gal Ofir, Gilad Meitav, Carmel Avraham, Sarah Melamed and Dr Gil Amitai, all of Soreks group in the Weizmann Institute of Sciences Molecular Genetics Department.

Prof Rotem Sorek is Head of the Knell Family Center for Microbiology; his research is also supported by the Willner Family Leadership Institute for the Weizmann Institute of Science; the Sagol Weizmann-MIT Bridge Program; the Schwartz/Reisman Collaborative Science Program; the Ben B and Joyce E Eisenberg Foundation; the Yotam Project; and the European Research Council.

View post:
Bacterial viperins prove effective against human viruses: Researchers - Express Pharma

Read More...

Virus-Fighting Enzymes in Bacteria Could Lead to Development of Highly Effective Antiviral Drugs Against COVID-19 – HospiMedica

Saturday, September 26th, 2020

Image: The viperins in bacteria have evolved to fight a variety of viruses (Photo courtesy of Weizmann Institute of Science)

A group of scientists at the Molecular Genetics Department at the Weizmann Institute of Science (Rehovot, Israel) has uncovered a gold mine of antiviral substances made by virus-fighting enzymes known as viperins. The molecules produced by the bacterial viperins are currently undergoing testing against human viruses such as the influenza virus and COVID-19.

Earlier studies conducted by the group as well as other scientists have revealed that bacteria have highly sophisticated immune systems, despite their microscopic size. In particular, they are equipped to fight off phages - viruses that infect bacteria. These differ from the kind that infect humans in their choice of targets, but they all consist of genetic material - DNA or RNA - that hijacks parts of the hosts replication machinery to make copies of themselves and spread.

The group of scientists have now found that some of these bacterial immune responses suggest evolutionary links to our own immune systems, and the present study in their lab shows the strongest evidence yet: They discovered that viperin antiviral enzymes - whose function in the human immune system was understood only two years ago - play a role in the immune system of bacteria.

In humans, viperin belongs to the innate immune system, the oldest part of the immune system in terms of evolution. It is produced when a signaling substance called interferon alerts the immune system to the presence of pathogenic viruses. The viperin then releases a special molecule that is able to act against a broad range of viruses with one simple rule: The molecule mimics nucleotides, bits of genetic material needed to replicate their genomes. But the viperin molecule is fake: It is missing a vital piece that enables the next nucleotide in the growing strand to attach. Once the faux-nucleotide is inserted into the replicating viral genome, replication comes to a halt and the virus dies.

This simplicity and broad action against many different viruses suggested viperins had been around for some time, but could they go back as far as our common ancestors with bacteria? The group used techniques that had been developed in their lab to detect bacterial sequences encoding possible viperins. They then showed that these viperins did, indeed, protect bacteria against phage infection. Based on the genetic sequences, the team was able to trace the evolutionary history of viperins. If the bacterial viperins prove effective against human viruses, then it may pave the way for the discovery of further molecules generated by bacterial immune systems that could be adopted as antiviral drugs for human diseases. Further studies are underway to determine which of the bacterial viperins could be best adapted to fighting human viruses, including, of course, COVID-19.

As we did decades ago with antibiotics - antibacterial substances that were first discovered in fungi and bacteria - we might learn how to identify and adopt the antiviral strategies of organisms that have been fighting infection for hundreds of millions of years, said Prof. Rotem Sorek from the Institutes Molecular Genetics Department.

Related Links:Weizmann Institute of Science

Go here to see the original:
Virus-Fighting Enzymes in Bacteria Could Lead to Development of Highly Effective Antiviral Drugs Against COVID-19 - HospiMedica

Read More...

Molecular Diagnostics Market Incredible Possibilities, Growth Analysis and Forecast To 2025 – The Daily Chronicle

Saturday, September 26th, 2020

Molecular diagnostics is a way of performing a diagnostic test to discover ailment, circumstance or infection in an artificial surroundings. Molecular diagnostic is one of the principal segments of in-vitro diagnostics marketplace. Molecular diagnostics is used to measure and stumble on the presence of genetic fabric related to specific disorder. It is used to identify DNA and RNA at molecular stage. Molecular diagnostics is a device to improve clinical effects and clinical decisions. Molecular diagnostic consists of all exams used to become aware of a disorder, by analyzing molecules such as DNA, protein or RNA in a fluid or tissue. In recent times molecular diagnostics is utilized in early detection of infectious sicknesses, most cancers and genetic ailment, by way of the usage of molecular and genetic technologies. Molecular diagnostics is likewise utilized in detection of abnormalities in pre-natal stage. Further, molecular diagnostic kits are utilized in pharmacogenetics trying out and blood donor screening.

The Global Molecular Diagnostics Market is expected to exceed more than US$ 12.50 billion by 2024 and will grow at a CAGR of more than 8.5% in the given forecast period.

You Can Browse Full Report @: https://www.marketresearchengine.com/reportdetails/molecular-diagnostics-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Roche Diagnostics (U.S.), QIAGEN N.V. (Netherlands), Hologic Inc. (U.S.), Grifols (Spain), Abbott Laboratories (U.S.), Siemens Healthcare (Germany), Becton, Dickinson and Company (U.S.), Beckman Coulter Inc. (U.S.), bioMrieux SA (France), and Cepheid Inc. (U.S.). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The molecular diagnostics market is segmented by product, by technology, by application and by end user analysis. Under the product and service segmentation it contains instruments, reagents and services & software. It uses different technologies such as polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA sequencing and next-generation sequencing, microarrays, mass pectrometry, flow cytometry, and electrophoresis. Molecular diagnostics techniques are used in different application such as infectious diseases, oncology, genetics, blood screening, microbiology, cardiovascular diseases, neurological diseases, and DNA fingerprinting. The end user of molecular diagnostics are reference laboratories, hospital laboratories, blood banks, local public health laboratories, home health agencies, nursing homes, point-of-care settings, and self-testing. The molecular diagnostics market is geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

The scope of the report includes a detailed study of global and regional markets for various types of molecular diagnostics market with the reasons given for variations in the growth of the industry in certain regions.

The Molecular diagnostics Market has been segmented as below:

The Molecular diagnostics Market is Segmented on the lines of Application Analysis, Product and service Segment Analysis, Technology Analysis, End-user Analysis and Regional Analysis. By Application Analysis this market is segmented on the basis of Infectious Diseases, Oncology, Genetics, Blood Screening, Microbiology and Others (Cardiovascular Diseases, Neurological Diseases, and DNA Fingerprinting). By Product and service Segment Analysis this market is segmented on the basis of Instruments, Reagents and Services & Software.

By Technology Analysis this market is segmented on the basis of Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization, DNA Sequencing and Next-generation Sequencing, Microarrays and Others (Mass Spectrometry, Flow Cytometry, and Electrophoresis). By End-user Analysis this market is segmented on the basis of Reference Laboratories sector, Hospital Laboratories sector and Others (Blood Banks, Local Public Health Laboratories, Home Health Agencies, Nursing Homes, Point-of-care Settings, and Self-testing) sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

The major driving factors of Global Molecular Diagnostics Market are as follows: Increasing application in blood screening Increasing prevalence of chronic and infectious diseases such as HIV and hepatitis Rising awareness and acceptance of personalized medicine

The restraining factors of Global Molecular Diagnostics Market are as follows:

Require more time for approval of many new molecular diagnostic tests Changing reimbursement regulations

This report provides:1) An overview of the Global Molecular Diagnostics Market and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for Global Molecular Diagnostics Market.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

Reasons to Buy this Report:1) Obtain the most up to date information available on all Global Molecular Diagnostics Market.2) Identify growth segments and opportunities in the industry.3) Facilitate decision making on the basis of strong historic and forecast of Global Molecular Diagnostics Market data.4) Assess your competitors refining portfolio and its evolution.

Request Sample Report from here: https://www.marketresearchengine.com/reportdetails/molecular-diagnostics-market

Table of Contents

1 INTRODUCTION

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Molecular Diagnostics Market Overview

6 Molecular Diagnostics Market, By Application

7 Molecular Diagnostics Market, By Technology

8 Molecular Diagnostics Market, By Products and Services

8.1 Introduction8.2 Reagents & Kits8.3 Instruments8.4 Software & Services

9 Molecular Diagnostics Market, By End User

10 Molecular Diagnostics Market, By Region

11 Competitive Landscape

12 Company Profiles

12.1 Introduction

12.2 Abbott Laboratories

12.3 Qiagen N.V.

12.4 Roche Diagnostics

12.5 Hologic, Inc.

12.6 Grifols

12.7 Siemens Healthcare

12.8 Becton, Dickinson and Company

12.9 Beckman Coulter Inc. (A Wholly Owned Subsidiary of Danaher Corporation)

12.10 Biomrieux Sa

12.11 Cepheid Inc.

Other Related Market Research Reports:

Minimally Invasive Medical Robotics Market is Determined to Cross US$ 44 Billion by 2022

Medical Tourism Market is Projected to Reach US$ 54.00 Billion by 2022

Medical Waste Management Market is Supposed to Reach US$ 21.00 Billion by 2024

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

View original post here:
Molecular Diagnostics Market Incredible Possibilities, Growth Analysis and Forecast To 2025 - The Daily Chronicle

Read More...

Kill fish to save fish: Behind Colorado’s effort to revive the Rio Grande cutthroat trout – The Colorado Sun

Saturday, September 26th, 2020

On a beautiful early September day, Ken Gierhart hiked a trail familiar since boyhood to Music Pass in the Sangre de Cristo mountains above Westcliffe. As he dropped off the saddle toward the Sand Creek lakes, he noticed people heading the opposite direction with fishing poles.

Hows the fishing? he asked one woman.

Theyre all dead, she replied, saying nothing more as she passed.

Puzzled, Gierhart came upon another woman heading away from the lakes and tried his question again.

There is no fishing, she said. Theyre all dead.

This time, the angler paused to explain that Colorado Parks and Wildlife, according to signs posted in the area, had used a chemical called rotenone to kill all the fish in the lakes and Sand Creek, which meanders south down the mountain before veering west to eventually disappear, after 13 miles, into the depths of the Great Sand Dunes.

The project is part of a long-planned strategy to restore the native Rio Grande cutthroat trout to waters where its numbers have dwindled toward the edge of extinction.

Increasingly scarce in a dwindling native range and hybridized with other species like non-native cutthroats, which had been stocked alongside it many years ago, the Rio Grande cutthroat eventually will be reintroduced to the mountain lakes and streams where it once thrived. But the process can be disconcerting especially to an unsuspecting hiker like Gierhart.

It wasnt until he got closer to Lower Sand Creek Lake that he saw the informational signs for himself. Then he headed toward the upper lake, following the trail that crosses the creek several times along the way. He said piles of dead earthworms filled seemingly every crevice in the rocks. And then it got worse.

It was horrifying at that level to see what had been done to the lake, Gierhart said. When I got to the lake I saw fish belly-up, carcasses on the bank where animals or birds had pulled them out.

Gierhart, a 54-year-old wholesale tree grower, hadnt heard anything about the fish management plan, and he stewed all the way back to his home in Westcliffe. There, he fired up his Facebook account and vented in a post that estimated thousands of dead fish and that attracted nearly 100 comments, most expressing concern over an undertaking they, too, seemed unaware of.

Ive always been preservation conscious, Gierhart said, still steamed a couple weeks later, but to see aquatic life dead like that, I started thinking about the watershed, the lasting effects, side effects.

The rant and its response caught the attention of CPW officials, who expressed frustration over response to a broad regional project that has been years in the making and which framed its intent in a compact signed in 2003 and renewed in 2013 by six federal entities, state agencies in Colorado and New Mexico and three American Indian tribal agencies. The agreement also received non-signatory support from two Trout Unlimited groups.

The Sand Creek drainage was officially listed in a 2013 strategy document.

In 2019, meetings on both the Westcliffe and Alamosa sides of the mountain yielded no opposition other than concern over the temporary loss of fishing and little public comment. The project moved ahead, though a year later than originally scheduled due to a late fish spawn.

Its something we need to do, said John Alves, the Durango-based senior aquatic biologist for CPWs Southwest Region. With only 11% of its historic range left, the Rio Grande cutthroat trout is always susceptible to petitions to list it as endangered, and also to extrication if there are events like fire. Its a constant process for us.

Joe Lewandowski, spokesman for CPWs Southwest Region, which includes the Sand Creek drainage, notes that the state agency has done similar projects before and will do more of them throughout Colorado.

We dont get a great deal of pleasure having to poison a stream, but it is necessary to restore native species, he said in an email to The Colorado Sun. This has been done in waters to restore the Rio Grande, greenback and the Colorado River cutthroat; and these projects will continue.

We know people are not happy to see dead fish, and it is confusing. Its very difficult often impossible to explain to the general public why we have to do these projects.

The intersection of history, science and politics of wildlife management can be complex. And while in this case the ultimate goal to restore the Rio Grande cutthroat to its native range is mostly a shared interest, the path to achieving it can be challenging.

After the 2003 conservation agreement, federal and state authorities started doing reconnaissance in 2004 to determine if the drainage could be restored. Geography that essentially isolated water flow, and therefore fish migration, proved fortuitous.

Its an ideal situation in a lot of regards, because its a closed system, said Fred Bunch, chief of resources management for the Great Sand Dunes National Park and Preserve, which takes in the Sand Creek drainage. The creeks have their headwaters high in the Sangres, they flow into those lakes and the lakes flow out to the dunes. Thirty-four square miles of sand is a pretty substantial fish barrier.

Bunch points to several reasons why reintroduction of the Rio Grande cutthroat looms important. First, theres federal policy that favors native species in national parks and preserves. Another has to do with the essential characteristics of a wilderness area. A third is for preservation of the species.

This is an ideal opportunity to restore 13 miles of habitat for the Rio Grande cutthroat trout, he said.

The stakeholders who signed the conservation agreement meet annually to discuss the status of its efforts. The key thing, Bunch said, is to prevent the listing of the Rio Grande cutthroat as an endangered species and ensure it has robust habitat.

And thats where politics can come in.

The Center for Biological Diversity, a nonprofit organization that claims roots in the fear that government authority alone will not always protect flora and fauna when powerful business interests can exert political leverage. (The timber industry was its founders nemesis.) Now, it contests threats to biodiversity on a range of levels, from climate change to encroachment of off-road vehicles.

The group has petitioned multiple times to place the Rio Grande cutthroat trout on the endangered species list, including one case thats still pending an appeal.

From the standpoint of state wildlife managers like Alves, who shares the groups desire to see the native species rebound, the fishs presence on the list represents another potential layer of bureaucracy that state workers on the ground would have to contend with.

Once a species is listed by the U.S. Fish and Wildlife Service, local agencies dont make decisions, he said. Theyre made by the federal government. For years, since the late 90s, there have been petitions to list the Rio Grande cutthroat trout. (The Center for Biological Diversity) sees listing as a way to get timber and mining off public lands.

That is true, said Noah Greenwald, the centers Portland, Oregon-based endangered species director.

Those things present a real threat to their habitat and to the species, so we want to make sure those things are done in a careful way or theres avoidance of trout habitat or, to the extent that theres damage, theres mitigation which is what the Endangered Species Act requires.

Aside from territorial concerns stemming from listing the species, both the center and the state agree on some key issues. The center supports and applauds the effort to repopulate the Sand Creek drainage with the native fish. But Greenwald also claims that his organizations petitions to list the Rio Grande trout spurred the state to take action to conserve them more than they were before.

We havent succeeded in putting them on the protected list, but weve pressured the state to do more for them, which is a benefit for the species, he said. Theyve done a tremendous amount of surveys and used staffing resources in an effort to avoid listing them. We dont think thats the right tradeoff. It makes more sense to list them and work for recovery.

The center doesnt even have problems with the kill-to-restock method, or the rotenone compound used to achieve it.

Greenwald calls the CPW a credible messenger with regard to the safety of rotenone.

We dont love having to use poisons, he said. But theres been a lot of work done on this issue, and there are not other effective means. As chemicals go, rotenone is pretty specific to fish. We definitely think it needs to be done carefully and we dont relish the thought of poison being used. But its the only way.

Make more coverage of Colorados environment possible by becoming a Colorado Sun member, starting at just $5 a month.

Although the battle over listing the fish persists, all sides celebrate the ideas that in the case of the Sand Creek drainage, the area could become a refugium for the species, where the fish could naturally multiply and be used as a source for future stocking or restoration if some other habitat experiences problems say, from wildfire.

So were doing it for many things, Bunch said. One is the philosophy of land managers, but theres also the species itself. Also theres a recreational piece. Its a great situation where a hiker can backpack in and catch native fish. Thats a pretty great situation to have, and thats what were shooting for.

From the start, the effort to restore the species has been a multipartner project, including federal, state and county agencies and even private groups like Trout Unlimited. Some of the early upfront money came from the National Park Service but functionally, the reintroduction process is a CPW project done in a national preserve. Cost of a helicopter, boats and other equipment is covered mostly by the state.

This year, phase one of the process got underway. But before fish and wildlife authorities took any action, they needed to know exactly how many different species they were dealing with in those waters that stretch from the Sand Creek lakes to the sand dunes.

And thats where science played a big role.

John Wood founded Pisces Molecular more than 20 years ago, just a few years before efforts began in earnest to restore the Rio Grande cutthroat trout.

Though it has just four people on staff, the Boulder-based biotech lab has clients all over the world, not to mention right in its backyard. Woods lab has worked with Colorado Parks and Wildlife on multiple different fish projects, including when in 2007, in conjunction with University of Colorado post-doc Jessica Metcalf, it discovered that CPWs stock of supposed greenback cutthroat trout which happens to be Colorados state fish were actually Colorado River cutthroat trout.

How do scientists figure out what species are in a waterway? One method is simply catching a sample of fish, clipping off the tiniest bits of their fins, and sending the material to a lab for DNA sequencing. Wood notes that can be laborious and difficult to get an accurate representation of the species makeup of a waterway.

The other option is environmental DNA testing. Just as humans regularly shed skin, hair, saliva and other sources of DNA, so do fish. Field researchers can collect a sample of water, filter out all the bits from the water, and send the gunked-up, DNA-laden filter to the lab for testing. These results will indicate the presence of species upstream of where the sample was taken.

Regardless of the type of sample, once it gets to the lab, Woods team uses polymerase chain reactions, also known as PCR, to check for species-specific genetic markers. For reference, this is the same kind of procedure used in the SARS-CoV-2 coronavirus test; Wood says its become a very sexy technique since the patent on PCR expired in the 2000s. And its remarkably precise; if one-tenth of a drop of a fishs DNA solution were mixed into an Olympic-sized swimming pool, Wood said, we would pick it up.

The only technical field that is changing as fast as computers is molecular genetics, so the sort of techniques that we use now are incredibly more sophisticated than when I was in graduate school, and I find that really fun, Wood said.

Theoretically, this could happen all in the field, but Wood says that it requires a lot of coordination, because you dont keep wild fish outside of their water body for very long. More often, its an iterative process between the lab and the wildlife managers testing the waterway, analyzing the results for the percent purity for individual fish or the population at large, then removing or restocking fish as needed, and doing it all over again.

Though Pisces was not directly involved with last months rotenone treatment, it has generally worked on identifying species in the Upper Sand Creek Lake drainage. In 2015, Woods team found evidence that the drainage had native Rio Grande cutthroat trout that were hybridizing with other subspecies, including Yellowstone cutthroat, greenback cutthroat and Colorado River cutthroat.

Wood called CPWs attitude on restoring native species enlightened, especially when compared to previous practices. Much of the 20th century was spent stocking the states waterways with outside fish such as rainbow trout, which are especially susceptible to whirling disease; when that struck the state in the 1990s, the rainbow trout population quickly spread it to other fish species, including native cutthroats. And this wasnt just in one or two rivers; in the process of moving fish around from waterway to waterway, stocking and other efforts inadvertently introduced the disease to 15 of the 17 hydrographic drainages in the state.

Along Sand Creek, the CPW found ponds on private property that harbored the parasites that transmit whirling disease. But the ponds were removed with stimulus funds during the Great Recession. Since they qualified as gravel pits, they could be remediated as abandoned mines. The whirling disease went away and the reintroduction plans moved forward.

Humans, when we mess with ecology, we generally make a mess, Wood said. So its probably philosophically better to do less interventions and strive to maintain whats there than presume that were smarter than Mother Nature.

That said, its not like leaving the river to rebound on its own would work. Part of it has to do with the different life cycles of fish species: brook trout, for example, spawn in the fall, giving them a full six months head start to grow before cutthroats spawn in the spring. And while rainbow trout spawn in the spring, like cutthroats, Wood notes that the jurys still out as to the impact of the two species interbreeding freely.

In other words: humans made this mess, and only humans can clean it up.

We now know more about genetics, we can discern finer level details, we have a longer history of how our attempts to alter ecologies tend not to work very well, so lets see if we can remediate some of the damage that weve done, Wood said.

In June, weeks before implementation of the first phase of the Rio Grande cutthroat project began, the CPW declared a fish emergency public salvage in the Sand Creek drainage. That tactic, which allows anglers to catch an unlimited number of fish from the waterways, has been used more times this summer, for a variety of reasons, than in the past 10 years.

On this occasion, the CPW wanted to let anglers help make best use of the fish before the chemical rotenone was administered to kill any that remained.

Alves, of the CPWs Southwest Region, noted that removing the bag limit seemed to be a particularly effective strategy in the lakes.

Get enough anglers out there, he said, they do a pretty good job.

The rest is left to rotenone, a plant-based compound effective only on gill-breathing organisms primarily fish and insects. The CPW workers secured the necessary permissions and trained to use it. During the first week of September, they began the process in the two high mountain lakes and the creeks below up to a point where waterfalls along Sand Creek provide a natural barrier to fish migration. Phase 2 of the operation will involve clearing Sand Creek from below the waterfalls to the Great Sand Dunes.

A helicopter from the Colorado Division of Fire Protection and Control had been busy fighting wildfires, but eventually was freed up to transport boats, motors, pumps and the 5-gallon buckets of rotenone itself to the lakes. Workers mixed the chemical with water. It was administered from a boat throughout the lake, in volumes dictated by the waters depth. The mixture shaded the water slightly white, a change that diminishes within several hours.

To apply rotenone to streams, workers spread out drips that added the rotenone/water solution to the flow every 15 seconds. A four-hour drip produced the desired solution throughout the streams.

The chemical works quickly. At one of the drip stations, Alves noticed that as soon as the organic green dye marker reached him from a drip point upstream, fish started dying. Workers also sprayed backwaters where fish might be lurking.

Rotenone, though extremely toxic to fish and some insects, is harmless to man and all warmblooded vertebrates, according to the journal Nature. Alves notes that it breaks down quickly in streams, but in lakes, at a water temperature of 50 degrees, takes about 28 days to decompose.

Then, the waiting begins. The dead fish decompose and, if all goes perfectly, the waterways will be clear for stocking. First, the water is tested environmental DNA sampling comes in handy here to make sure no fish survived that could taint the reintroduction of the native Rio Grande.

Youve got to wait and see,Alves said. Well do a lot of sampling, electrofishing in the streams, gill netting in the lakes, probably use environmental DNA, and test to see if there are genetic markers. We use that as a confirming tool.

If any fish remain, CPW will come back and repeat the process.

If theres zero live fish, Alves said, well start to restock in the fall.

Typically, CPW uses airplanes to stock the high mountain lakes. Workers on foot or on horseback, and sometimes by helicopter, stock the streams. By stocking fish in a variety of age groups, managers can hasten the turnaround.

The Sand Creek drainage, with its hiking trails and beautiful vistas, is a highly used area, Alves said. Though remote, its only about an hour-and-a-half hike in from the trail head. What he wants people to understand is that what the CPW is doing is definitely the right thing. Yes, the fish are all gone but thats only temporary.

As soon as we can, well put in Rio Grande cutthroat trout, really a pretty fish, growing to the same size theyre used to catching, a 15- or 16-inch fish, he said. So theyre temporarily losing their opportunity, but itll come back. I predict within five years, theyll see really good cutthroat trout in the lakes.

Support local journalism around the state.Become a member of The Colorado Sun today!

Read more:
Kill fish to save fish: Behind Colorado's effort to revive the Rio Grande cutthroat trout - The Colorado Sun

Read More...

Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products – GlobeNewswire

Saturday, September 26th, 2020

Alec Hayes, Vice President Technology & Products

Alec Hayes, Vice President Technology & Products

DURHAM, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announcedthat Alec Hayes, Ph.D., has joined Elo Life Systems as Vice President of Technology and Products. In his role, Alec will be responsible for Elos research and development pipeline and strategic expansion of Elos integrated suite of capabilities to enable accelerated product development.

Through thoughtful analysis of opportunities and challenges in the industry, Elo has embarked on impactful programs of immediate relevance to human nutrition and the health of our planet, commented Fayaz Khazi, Ph.D., Chief Executive Officer of Elo Life Systems. Alecs experience at the nexus of food and human health will be instrumental as we fast-track Elos pipeline and long-term vision.

With a product-ready genome editing platform, world-class expertise in target discovery, and an end-to-end infrastructure that enables expedited trait validation, Elo is uniquely positioned to improve human health through rapid product development, said Alec Hayes. I look forward to joining the incredibly talented group at Elo, working to create sustainable production of a more nutritious, and climate-resilient food supply.

Prior to joining Elo,Alec served as the Technical Director of Agricultural Technologies at The Coca-Cola Company in Atlanta. There, he helped drive long-term strategic opportunities in beverage innovation and address agricultural supply chain challenges. Prior to that, Alec held technical leadership roles at PepsiCo and Altria and brings over 20 years of industry experience in translational agriculture, developing plant-based strategies to advance consumer-focused product solutions.Alec holds a Ph.D. in plant molecular genetics from Virginia Tech.

About Elo Life Systems, Inc.Elos mission is to create novel products that enhance the nutrition and diversity of the global food supply. To address agricultural needs, Elo partners with stakeholders in the food systems value chain to bridge gaps and meet needs across agricultural productivity, nutritional demand, food security, climate-resilience, and human wellness. Elo Life Systems, Inc. is a wholly owned subsidiary of Precision BioSciences, Inc. (NASDAQ: DTIL). To learn more about Elo Life Systems please visit http://www.elolife.ag.

Investor and Media Contact:Maurissa MessierSenior Director, Corporate Communicationsmmessier@elolife.ag

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/620459d9-8c82-48a2-ae64-e9ea9d183566

Read more:
Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products - GlobeNewswire

Read More...

Zelis and Concert Genetics Launch Genetic Testing Claim Editing Solution – Business Wire

Saturday, September 26th, 2020

BEDMINSTER, N.J. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Zelis, the healthcare industrys leading claims cost and payments optimization platform with superior technology and solutions to price, pay and explain claims, and Concert Genetics, a technology company dedicated to advancing precision medicine, have launched a claim editing solution for the complex and rapidly-growing area of genetic testing.

The solution embeds Concerts claim editing capabilities, which are powered by robust genetic testing market data and machine learning, into Zelis existing claim editing platform. This leading-edge platform already contains more than 18 million edits sourced to national coding standards. The partnership adds specialized content in genetic testing that other platforms lack, enabling Zelis and Concert to improve coding and billing accuracy of these complex and ambiguous genetic test claims before they are paid.

Our clients are experiencing higher costs due to the complexity of managing the variability of genetic testing codes and volume of new tests entering the market, said R. Andrew Eckert, Zelis CEO. Combining our payment integrity expertise with Concerts precision technology will enable us to proactively identify inaccurate claims and continue to support our clients with innovative solutions to reduce costs.

This solution comes at a critical time, as the availability and demand for genetic tests grow with the global genetic testing market expected to reach $17.6 billion by 2025, from $7.5 billion in 2017.1 Additionally, the total number of available genetic testing products has surpassed 150,000, up from around 10,000 in 2012. Meanwhile, much of the growth in volume is represented by multi-gene panel tests, which are particularly difficult for health plans to process in an efficient and accurate way because they are billed using multiple billing codes in widely varying combinations. Some categories of genetic tests are billed in thousands of different code combinations.

The pace of advancement in the science and clinical application of genetics is remarkable, and the healthcare system has had difficulty keeping up, said Rob Metcalf, CEO of Concert Genetics. Concert has assembled the data and digital infrastructure to enable transparency, connectivity, and value in this space, and we are pleased to partner with Zelis to make our technology available to its clients.

A key enabler of this claim editing solution is its ability to match complex claims with multiple billing codes back to its catalog of tests on the market. The combined solution is available to Zelis clients effective immediately.

About Zelis

Zelis is the healthcare industrys leading claims cost and payments optimization platform with superior technology and solutions to price claims, pay claims and explain claims, all at enterprise scale on a claim-by-claim basis. Zelis leverages proprietary technology, robust analytics, extensive payment and provider networks, and innovative claim savings channels to deliver to the industry superior administrative and medical cost savings. Zelis was founded on a belief that there is a better way to determine the cost of a healthcare claim, manage payment related data, and make the claim payment. Zelis provides the industrys only comprehensive, integrated platform to take a claim through the entire pre-payment to payments lifecycle. Zelis ~1000 associates serve more than 700 payor clients, including the top-5 national health plans, Blues plans, regional health plans, TPAs and self-insured employers, and more than 1.5 million providers. Zelis delivers more than $5B of claims savings, $50B of provider payments and 500 million payment data communications annually.

About Concert Genetics

Concert Genetics is a software and managed services company that advances precision medicine by providing the digital infrastructure for reliable and efficient management of genetic testing. Concerts market-leading genetic test order management platform leverages a proprietary database of the U.S. clinical genetic testing market today more than 150,000 testing products and genetic testing claims from more than 100 million lives. Learn more at http://www.ConcertGenetics.com.

1 Allied Market Research report, Genetic Testing Market by Type (Predictive Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), and Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others): Global Opportunity Analysis and Industry Forecast, 20182025

Read the original here:
Zelis and Concert Genetics Launch Genetic Testing Claim Editing Solution - Business Wire

Read More...

Houston sampling wastewater to track spread of COVID-19 – Associated Press

Saturday, September 26th, 2020

HOUSTON (AP) Results from a program thats testing Houstons wastewater to monitor the local spread of the coronavirus have shown that it could be a faster way of detecting outbreaks in the nations fourth-largest city, officials said Thursday.

Since May, the city and scientists from Rice University and Baylor College of Medicine have tested wastewater from the citys 39 treatment plants. Studies indicate genetic material from the virus can be recovered from the stools of about half of patients with the COVID-19 virus. Wastewater analysis looks for that genetic material.

The goal is to help develop an early warning system, allowing the health department to identify the citys COVID-19 hot spots sooner and put measures in place to slow the spread of this disease, said Mayor Sylvester Turner.

During the summer, Houston had a surge in coronavirus cases as the areas intensive care units were filled with patients. Since then, hospitalizations have decreased and the citys positivity rate for the virus has gone from a high of nearly 26% in July to 6.1% as of last week.

Turner has said that while the numbers are better, the city is still reporting positive cases and deaths at levels higher than the spring. Houston has reported 72,196 cases and 1,069 deaths as of Thursday.

Houston is among communities around the world that have implemented wastewater testing programs to help deal with the virus spread. Colleges across the U.S. are also testing wastewater to detect outbreaks.

The wastewater data can show which parts of Houston have a higher virus load, prompting the health department to send teams to those areas that can go door to door and inform residents and encourage people to get tested, said Dr. David Persse, Houstons health authority.

This will give us that early warning that we may have otherwise missed so we empower people to take care of themselves, Persse said.

The wastewater testing can also provide a more current view of whats going on with the virus in the city. The testing is done weekly and the results come back that same week. By comparison, 40% or more of testing data from nasal swabs are more than 2 weeks old, Persse said.

The wastewater data can be used to look at specific locations.

After COVID-19 cases were found at a homeless shelter earlier this year, the city monitored the facilitys wastewater and was able to detect when the virus came back a second time, Persse said.

This isnt the first time wastewater surveillance has been used in Houston to detect a viral outbreak. In 1962, Joseph Melnick, who worked at Baylor College of Medicine and was a pioneer in polio research, realized polio could be detected in wastewater and started sampling it.

That research prompted Melnick to push for a quicker use of the then-new oral polio vaccine, which helped stop outbreaks of the disease, said Anthony Maresso, an associate professor of molecular virology and microbiology at Baylor College of Medicine.

So, we can learn from this lesson of history of the importance of doing such measures for public health interventions, Maresso said.

State officials reported 3,840 new confirmed cases of the virus Thursday, bringing the Texas total since it began tracking the pandemic in early March to nearly 724,000. Of those, the Department of State Health Services estimated that 66,483 cases were now active and 3,204 people are hospitalized. Also, 138 new COVID-19 deaths were reported Thursday, bringing the states pandemic death toll to 15,267.

___

Follow Juan A. Lozano on Twitter: https://twitter.com/juanlozano70

Link:
Houston sampling wastewater to track spread of COVID-19 - Associated Press

Read More...

Insights on the Predictive and Presymptomatic Testing Global Market to 2027 – Featuring Mapmygenome, Myriad Genetics & Pathway Genomics Among…

Saturday, September 26th, 2020

DUBLIN--(BUSINESS WIRE)--The "Predictive and Presymptomatic Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The publisher brings years of research experience to the 6th edition of this report. The 142-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Predictive and Presymptomatic Testing Market to Reach $7.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Predictive and Presymptomatic Testing estimated at US$4.1 Billion in the year 2020, is projected to reach a revised size of US$7.7 Billion by 2027, growing at a CAGR of 9.6% over the period 2020-2027.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 12.7% CAGR

The Predictive and Presymptomatic Testing market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 12.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.6% and 8.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/f4gfph

Visit link:
Insights on the Predictive and Presymptomatic Testing Global Market to 2027 - Featuring Mapmygenome, Myriad Genetics & Pathway Genomics Among...

Read More...

Sex is real – aeon.co

Saturday, September 26th, 2020

Its uncontroversial among biologists that many species have two, distinct biological sexes. Theyre distinguished by the way that they package their DNA into gametes, the sex cells that merge to make a new organism. Males produce small gametes, and females produce large gametes. Male and female gametes are very different in structure, as well as in size. This is familiar from human sperm and eggs, and the same is true in worms, flies, fish, molluscs, trees, grasses and so forth.

Different species, though, manifest the two sexes in different ways. The nematode worm Caenorhabditis elegans, a common laboratory organism, has two forms not male and female, but male and hermaphrodite. Hermaphroditic individuals are male as larvae, when they make and store sperm. Later they become female, losing the ability to make sperm but acquiring the ability to make eggs, which they can fertilise with the stored sperm.

This biological definition of sex has been swept up into debates over the status of transgender people in society. Some philosophers and gender theorists define a woman as a biologically female human being. Others strongly disagree. Im addressing those who reject the very idea that there are two biological sexes. Instead, they argue, there are many biological sexes, or a continuum of biological sexes.

Theres no need to reject how biologists define the sexes to defend the view that trans women are women. When we look across the diversity of life, sex takes stranger forms than anyone has dreamt of for humans. The biological definition of sex takes all this in its stride. It does so despite the fact that there are no more than two biological sexes in any species youre likely to have heard of. To many people, that might seem to have conservative implications, or to fly in the face of the diversity we see in actual human beings. I will make clear why it does not.

I call this the biological definition of sex because its the one biologists use when studying sex that is, the process by which organisms use their DNA to make offspring. Many philosophers and gender theorists will protest at making the creation of offspring foundational to how we define sex or distinguish different sexes. Theyre surely right that sex as a social phenomenon is much richer than that. But the use of DNA to make offspring is a central topic in biology, and understanding and explaining the diversity of reproductive systems is an important scientific task. Gender theorists are understandably worried about how the biology of sex will be applied or misapplied to humans. What they might not appreciate is why biologists use this definition when classifying the mind-stretching forms of reproduction observed in limpets, worms, fish, lizards, voles and other organisms and they might not understand the difficulties that arise if you try to use another definition.

Many people assume that if there are only two sexes, that means everyone must fall into one of them. But the biological definition of sex doesnt imply that at all. As well as simultaneous hermaphrodites, which are both male and female, sequential hermaphrodites are first one sex and then the other. There are also individual organisms that are neither male nor female. The biological definition of sex is not based on an essential quality that every organism is born with, but on two distinct strategies that organisms use to propagate their genes. They are not born with the ability to use these strategies they acquire that ability as they grow up, a process which produces endless variation between individuals. The biology of sex tries to classify and explain these many systems for combining DNA to make new organisms. That can be done without assigning every individual to a sex, and we will see that trying to do so quickly leads to asking questions that have no biological meaning.

While the biological definition of sex is needed to understand the diversity of life, that doesnt mean its the best definition for ensuring fair competition in sport or adequate access to healthcare. We cant expect sporting codes, medical systems and family law to adopt a definition simply because biologists find it useful. Conversely, most institutional definitions of sex break down immediately in biology, because other species contradict human assumptions about sex. The United States National Institutes of Health (NIH) uses a chromosomal definition of sex XY for males and XX for females. Many reptiles, such as the terrifying saltwater crocodiles of northern Australia, dont have any sex chromosomes, but a male saltie has no trouble telling if the crocodile that has entered his territory is a male. Even among mammals, at least five species are known that dont have male sex chromosomes, but they develop into males just fine. Gender theorists have extensively criticised the chromosomal definition of human sexes. But however well or badly that definition works for humans, its an abject failure when you look at sex across the diversity of life.

The same is true of phenotypic sex, the familiar idea that sex is defined by the typical physical characteristics (phenotypes) of males and females. Obviously, this approach will produce completely different definitions of male and female for humans, for worms, for trees and so forth. Incubating eggs inside your body, for example, is a female characteristic in humans but a male one in seahorses. That doesnt mean that human institutions cant use the phenotypic definition. But it isnt useful when studying the common patterns in the genetics, evolution and so forth of female humans, female seahorses and female worms.

Understanding the complex ways in which chromosomes and phenotypes relate to biological sex will make clear why the biological definition of sex shouldnt be the battleground for philosophers and gender theorists who disagree about the definition of woman. There might be very good reasons not to define woman in this way, but not because the definition itself is poor biology.

Why did sexes evolve in the first place? Biologists define sex as a step towards answering this question. Not all species have biological sexes, and biology seeks to explain why some do and others dont. The fact that no species has evolved more than two biological sexes is also a puzzle. It would be quite straightforward to engineer a species that has three, but none has evolved naturally.

Many species reproduce asexually, with each individual using its own DNA to create offspring. But other species, including our own, combine DNA from more than one organism. Thats sexual reproduction, where two sex cells gametes merge to make a new individual. In some species, these two gametes are identical; many species of yeast, for example, make new individuals from two, identical gametes. They reproduce sexually, but they have no sexes, or, if you prefer, they have only one sex. But in species that make two different kinds of gamete and where one gamete of each kind is needed to make a new organism there are two sexes. Each sex makes one of the two kinds of gamete.

In complex multicellular organisms, such as plants and animals, these two kinds of gamete are very different. One is a large, complex cell, what wed typically call an egg. Its similar to the eggs produced by asexual species, which can develop into a new organism all on their own. Many species of insect and some lizards, snakes and sharks can reproduce using just an egg cell. The other kind of gamete is a much smaller cell that contains very little beyond some DNA and some machinery to get that DNA to the larger gamete. We are familiar with these two kinds of gametes from human eggs and sperm.

Theres no obvious reason why complex multicellular organisms need to have two kinds of gamete, or why these two kinds are so different in size and structure. Its perfectly possible to make three or more different kinds of gamete, or gametes that vary continuously, just as people vary continuously in height. One question that biologists seek to answer, then, is why those forms of sexual reproduction arent observed in complex organisms such as animals and plants.

Earthworms are hermaphrodites: one part of the worm produces sperm and another part produces eggs

When a species produces two different kinds of gamete, biologists call this anisogamy, meaning not-equal-gametes. Some anisogamic species have separate sexes, like humans do, where each individual can produce only one kind of gamete. Other anisogamic species are hermaphrodites, where each individual produces both kinds of gamete. Because they produce two kinds of gametes, hermaphroditic species still have two biological sexes they simply combine them in one organism. When a biologist tells you that earthworms are hermaphrodites, they mean that one part of the worm produces sperm and another part produces eggs.

Some single-celled and very simple multicellular organisms have evolved something called mating types. These are gametes that are identical in size and structure, but in which the genome of each gamete contains genetic markers that affect which other gametes it can combine with. Typically, gametes with the same genetic marker cant recombine with one another. Some species have many hundreds of these mating types, and newspapers often report research into this phenomenon under headlines such as: Scientists discover species with hundreds of sexes! But, formally, biologists refer to these as mating types, and reserve the term sexes for gametes that are different in size and structure.

Why distinguish between these two phenomena? One reason is that the evolution of anisogamy gametes that differ in size and structure explains the later evolution of sex chromosomes, sex-associated physical characteristics and much more. But the existence of mating types doesnt have these dramatic knock-on evolutionary effects. Another reason to keep the distinction is that anisogamy and mating types are thought to have evolved via different evolutionary processes. One theory is that anisogamy appeared when mating-type genome markers somehow became linked to genes that controlled the size of the gamete, or mutated in some way that affected gamete size. These differences in gamete size would then kickstart the evolution of sexes.

The evolution of sex seems to be strongly associated with multicellularity, so the obvious place to look for a shift from mating types to sexes is in organisms that sit at the multicellular boundary such as algae, which sometimes exist as single-celled organisms, and sometimes as colonies of cells. And indeed, there are species of algae where gametes are just a little bit anisogamous, blurring the distinction between mating types and sexes. Theres much we dont know about how sex evolved, and how it might have evolved differently across species. But the point is that sexes and mating types are very different phenomena, with different causes and consequences.

The fact that sex evolved in some species but not others tells us something important about how biologists think about sex. Many cultures take the difference between male and female to be something fundamental, and label other natural phenomena such as the Sun and the Moon as male or female. But for biologists, the separation between male and female is no more fundamental or universal than photosynthesis or being warm-blooded. Some species have evolved these things, and some havent. They exist when they do only because of the local advantages they afforded in evolutionary competition.

So why did some species evolve two, distinct sexes? To answer this question, we need to forget about creatures with complex sex organs and mating behaviours. These evolved later. Instead, think of an organism that releases its gametes into the sea, such as coral, or into the air, such as fungal spores. Next, consider that there are two goals that any gamete must achieve if its to reproduce sexually. The first is finding and recombining with another gamete. The second is producing a new individual with enough resources to survive. One widely accepted idea, then, is that the evolution of sexes reflects a trade-off between these goals. Because no organism has infinite resources, organisms can either produce many small gametes, making it more likely that some of them will find a partner, or produce fewer but larger gametes, making it more likely that the resulting individual will have what it needs to survive and thrive.

Since the 1970s, this idea has been used to model how anisogamic species might have evolved from species with only one kind of gamete. As mutations introduce differences in gamete size, two winning strategies emerge. One is to produce a large number of small gametes too small to create viable offspring unless they recombine with a larger, well-provisioned gamete. The other winning strategy is to produce a few, large, well-resourced gametes that can create viable offspring, no matter how small the recombinant they end up merging with. Intermediate approaches, such as producing a moderate number of moderately well-provisioned gametes, dont do well. Organisms that try to follow the middle way end up with gametes less likely to find a partner than smaller gametes, and more likely to have insufficient resources than larger gametes. When the two successful complementary strategies have evolved, fresh evolutionary pressures make the gametes even more distinct from one another. For example, it can be advantageous for the small gametes to become more mobile, or for the large, immobile gametes to send signals to the mobile ones.

Once anisogamy has evolved, it shapes many other aspects of reproductive biology. Most species of limpet shellfish that you see on rocks at the beach are sequential hermaphrodites. When young and small they are male, and when mature and large they become female. This is believed to be because small limpets dont have sufficient resources to produce large female gametes, but theyre capable of producing the smaller male ones. In some other species, successful males can arrest their growth and remain small (and male) for their entire life.

Chromosomes arent male or female because these bits of DNA define biological sex. Its the other way around

Sequential hermaphroditism occurs in the opposite direction too. Australian snorkellers love to spot the large blue males of the eastern blue groper, but its rare to see more than one. Most groper are smaller, brown females. They are all born female and become sexually mature after a few years, when 20 or 30 cm in length. At around 50 cm, they change sex and acquire other male characteristics, such as being blue. Unlike the limpet, the main problem facing a male groper is controlling a territory on the reef, so becoming male when youre small is a losing strategy.

Biology aims to understand the extraordinary diversity of ways in which organisms reproduce themselves, as well as to identify common patterns, and to explain why they occur. In general, organisms become sexually mature when they reach an optimal size for reproduction. This optimal size is often different for the two sexes, because the two sexes represent divergent strategies for reproduction. The limpet and the groper are two of many examples. In constructing these explanations, biological sex is defined as the production of one type of viable anisogamous gamete. If we defined sex in some other way, it would be hard to see the common patterns across the diversity of life, and hard to explain them.

So-called sex chromosomes, such as the XX and XY chromosome pairs seen in humans, are often brandished as something thats fundamental to sex. Its partly the inadequacy of this definition that drives scepticism about the existence of two, discrete biological sexes. Molecular genetics is likely to require a shift from binary sex to quantum sex, with a dozen or more genes each conferring a small percentage likelihood of male or female sex that is still further dependent on micro- and macroenvironmental interactions, writes the gender scholar Vernon Rosario.

But any biologist already knows that theres more to sex determination than chromosomes and genes, and that male and female sex chromosomes are neither necessary nor sufficient to make organisms male and female. Several species of mammal, all rodents of one kind or another, have completely lost the male Y chromosome, but these rats and voles all produce perfectly normal, fertile males. Other groups of species, such as crocodiles and many fish, have neither sex chromosomes nor any other genes that determine sex. Yet they still have two, discrete biological sexes. The Australian saltwater crocodile, whom we met before, lays eggs that are very likely to develop into gigantic, highly territorial males if incubated between 30 and 33 degrees Celsius. At other temperatures, genetically identical eggs develop into much smaller females.

The reality is that chromosomes arent called male or female because these bits of DNA define biological sex. Its the other way around in some species that reproduce using two discrete sexes, those sexes are associated with different bits of DNA. But in other species this association is either absent or unreliable. Medical institutions use a chromosomal definition of sex because they judge, rightly or wrongly, that this is a reliable way of categorising humans. But humans really arent the best place to start when trying to understand sex across the diversity of life.

So much for genes. But perhaps sex could be defined by the physical characteristics that organisms develop, which then add up to constitute an organisms sex? An organism with more female than male characteristics would be more female than male and vice-versa. Thats a reasonable way to think about sex, and this idea of phenotypic sex is widely used. But if we apply the biological definition of sex, some of the individuals who are in the middle as far as sex-associated characteristics go are bona fide members of one biological sex. Others are not clearly members of either biological sex.

Nothing in the biological definition of sex requires that every organism be a member of one sex or the other. That might seem surprising, but it follows naturally from defining each sex by the ability to do one thing: to make eggs or to make sperm. Some organisms can do both, while some cant do either. Consider the sex-switching species described above: what sex are they when theyre halfway through switching? What sex are they if something goes wrong, perhaps due to hormone-mimicking chemicals from decaying plastic waste? Once we see the development of sex as a process and one that can be disrupted it is inevitable that there will be many individual organisms that arent clearly of either sex. But that doesnt mean that there are many biological sexes, or that biological sex is a continuum. There remain just two, distinct ways in which organisms contribute genetic material to their offspring.

Whats more, the physical characteristics of an organism can be labelled as male or female only if there is already a definition of sex. Whats so male about a groper being blue as opposed to brown? Many male organisms are brown. Whats so female about incubating eggs in a womb? After all, in many pipefish and seahorse species the male incubates the eggs in his brood pouch. What makes this part of the hermaphroditic earthworm male and that part female? Gender studies scholars have noticed this logical discrepancy, and some have gone on to argue that the sexes must therefore be defined in terms of gender. But from a biological perspective, what makes an observable physical characteristic male or female is not its association with gender, but its association with something more tangible: the production of one or other of the two kinds of gamete.

This explains why the existence of individuals with combinations of male and female characteristics doesnt show that biological sex is a continuum. These organisms have a combination of characteristics associated with one biological sex and characteristics associated with the other biological sex. They do not have some part of the ability to make small gametes combined with some part of the ability to make large gametes. Their phenotypic sex might be intermediate, but their biological sex is not. Being fully biologically male and fully biologically female hermaphroditic can be an effective evolutionary strategy, and we have encountered several hermaphroditic species already. But making both kinds of gametes incompletely would be an evolutionary dead-end.

Like phenotypic characteristics, sex chromosomes can be more or less reliably associated with biological sex. The eastern three-lined skink, an Australian lizard, has sex chromosomes, and under some circumstances XY skinks become male and XX skinks become female, just as in humans. But in cold nests, every skink becomes male, whatever their chromosomes. By becomes male, biologists mean that they grow up to produce small gametes sperm.

No animal is conceived with the ability to make sperm or eggs (or both). This ability has to grow

This effect of temperature on sex is not surprising, as many reptile species produce genetically identical offspring whose sex is determined by incubation temperature. Whats more surprising is that varying the size of the egg yolk in this species of skink can produce both sexes with the wrong sex chromosomes: XX males and XY females. The skink seems to have three mechanisms for determining sex chromosomes, temperature and hormones in the yolk. This is not a mere quirk of nature. The skink is one of many species that actively control the sex of their offspring, responding to environmental cues that predict whether male or female offspring have better chances of surviving and reproducing.

If all species were like the skink, we probably wouldnt label sex chromosomes as male or female. After all, we dont think of extreme nest temperatures as female and intermediate temperatures as male, merely because they produce male and female crocodiles or male and female geckos. We think of sex chromosomes as male or female because we focus on species where they are reliably associated with the production of male or female gametes.

Sex chromosomes play much the same role in sex determination as nest temperatures and hormones. Theyre simply mechanisms that organisms use to turn genes on and off in offspring so that they develop a biological sex. No animal is conceived with the ability to make sperm or eggs (or both). This ability has to grow, through a cascade of interactions between genes and environments. In some species, once an individual acquires a sex, it remains that sex for the rest of its life. In others, individuals can switch sex one or more times. But in every case, the underlying mechanisms are designed to grow organisms that make either male or female gametes (or both). The other changes the body undergoes as it becomes male, female or hermaphroditic are designed to fit the reproductive strategies that this species has evolved.

These mechanisms by which organisms develop or switch biological sex are complex, and many factors can interfere with them. So they produce a lot of phenotypic diversity. Sometimes, organisms grow up able to make fertile gametes, but otherwise atypical for their biological sex. Sometimes, they grow up unable to make fertile gametes of either kind. This is usually an accident, but sometimes by design. In bees, eggs that arent fertilised develop into males, so male bees have half as many chromosomes as female bees. Meanwhile, all fertilised eggs start to develop into females, but most of them never complete their sexual development. The queen sends chemical signals that block the development of the worker bees ovaries at an early stage. So worker bees are female in the extended sense that they would develop into fertile females if they werent actively prevented from doing so. Occasionally, worker bees manage to evade these controls and lay their own eggs. They are not popular with beekeepers, who select against these mutant strains.

The diversity of outcomes in individual sexual development doesnt mean that there are many biological sexes or that biological sex is a continuum. Whatever the merits of those views for chromosomal sex or phenotypic sex, they are not true of biological sex. A good way to grasp this is to imagine a species that really does have three biological sexes. Biotechnologists have proposed curing mitochondrial diseases by removing the nucleus from an egg with healthy mitochondrial DNA, and inserting a new nucleus containing the nuclear DNA from an unhealthy egg and the nuclear DNA from a sperm. The resulting child would have three genetic parents.

Now imagine if there was a whole species like this, where three different kinds of gametes combined to make a new individual a sperm, an egg and a third, mitochondrial gamete. This species would have three biological sexes. Something like this has actually been observed in slime moulds, an amoeba that can, but need not, get its mitochondria from a third parent. The novelist Kurt Vonnegut imagined an even more complex system in Slaughterhouse-Five (1969): There were five sexes on Tralfamadore, each of them performing a step necessary in the creation of a new individual. But the first question a biologist would ask is: why havent these organisms been replaced by mutants that dispense with some of the sexes? Having even two sexes imposes many extra costs the simplest is just finding a mate and these costs increase as the number of sexes required for mating rises. Mutants with fewer sexes would leave more offspring and would rapidly replace the existing Tralfamadorians. Something like this likely explains why two-sex systems predominate on Earth.

We can also imagine a species where biological sex really does form a continuum. Recall that some algae have slightly anisogamous gametes, much closer together than sperm and eggs. We can imagine a more complex organism using this system, with some slightly smaller gametes and some slightly larger ones. Successful reproduction might require two gametes that, when added together, are big enough but not too big. But the sexually reproducing plants and animals that actually exist all have just two, very different kinds of gamete male and female. Theyre not merely different in size, theyre fundamentally different in structure. This is the result of competition between organisms to leave the greatest number of genetic descendants. In complex multicellular organisms such as plants and animals, we know of only three successful reproductive strategies: two biological sexes in different individuals, two biological sexes combined in hermaphroditic individuals, and asexual reproduction. Some species use one of these strategies, some use more than one.

Human beings have come up with many ways to classify the diversity of individual outcomes from human sexual development. People who want to apply the biological definition of sex to humans should recognise that its ill-suited to do what many human institutions want, which is to sort every individual into one category or another. What sex are worker bees? They are sterile workers whose genome was designed by natural selection to terminate ovary development on receipt of a signal from the queen bee. They share much of the biology of fertile female bees but if someone wants to know Are worker bees really female?, theyre asking a question that biology simply cant answer.

Nor is being a sterile worker a third biological sex alongside male and female. This is easier to see in ants, where there is more than one sterile caste. Workers, soldiers, queens and male flying ants each have specialised bodies and behaviour, but there are not four biological sexes of ant. Workers and soldiers are both female in an extended sense, but not in the full-blown sense that queen ants are female. There is a human imperative to give everything a sex, as mentioned above, but biology doesnt share it.

The biological definition of sex wasnt designed to ensure fair sporting competition, or settle healthcare disputes

Juvenile organisms and postmenopausal human females also cant produce either kind of gamete. Juveniles are assigned to the sex they have started to grow into. But once again, this is more complicated than it seems when we focus only on humans. In almost all mammals, sexual differentiation is initiated by a region of the Y chromosome, so a mammalian egg can become either male or female. In birds, its the other way around the egg carries the sex-determining W chromosome, so sperm can become either male or female. After fertilisation, therefore, we can say that an individual mammal or bird has a sex in the sense that it has started to grow the ability to produce either male or female gametes. With a crocodile or a turtle, though, wed have to wait until nest temperature had its sex-determining effect. But that doesnt mean that we need to create a third biological sex for crocodile eggs!

More importantly, nothing guarantees that any of these organisms, including those with sex chromosomes, will continue to grow to the point where they can actually produce male or female gametes. Any number of things can interfere. From a biological point of view, there is nothing mysterious about the fact that organisms have to grow into a biological sex, that it takes them a while to get there, and that some individuals develop in unusual or idiosyncratic ways. This is a problem only if a definition of sex must sort every individual organism into one sex or another. Biology doesnt need to do that.

In human populations, there are plenty of individuals whose sex is hard to determine. Biologists arent blind to this. The definition of biological sex is designed to classify the human reproductive system and all the others in a way that helps us to understand and explain the diversity of life. Its not designed to exhaustively classify every human being, or every living thing. Trying to do so quickly leads to questions that have no biological meaning.

Human societies cant delegate to biology the job of defining sex as a social institution. The biological definition of sex wasnt designed to ensure fair sporting competition, or to settle disputes about access to healthcare. Theorists who want to use the biological definition of sex in those ways need to show that it will do a good job at the Olympics or in Medicare. The fact that its needed in biology isnt good enough. On the other hand, whatever its shortcomings as an institutional definition, the concept of biological sex remains essential to understand the diversity of life. It shouldnt be discarded or distorted because of arguments about its use in law, sport or medicine. That would be a tragic mistake.

The authors research is supported by the Australian Research Council and the John Templeton Foundation. He would also like to thank Nicole Vincent, Jussi Lehtonen, Stefan Gawronski and Joshua Christie for their feedback on earlier drafts.

See original here:
Sex is real - aeon.co

Read More...

UK research getting to bottom of COVID clots – ABC 36 News – WTVQ

Friday, September 18th, 2020

The research led by Jeremy Wood, Zach Porterfield and Jamie Sturgill in the Department of Internal Medicine; Beth Garvy in Microbiology, Immunology & Molecular Genetics; and Wally Whiteheart in Molecular & Cellular Biochemistry, suggests localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients.

The study also provides evidence suggesting the risk of thrombosis could persist after the infection clears.

The study examined the blood of 30 COVID-19 patients including 15 who were inpatients in the intensive care unit, and 15 who received care as outpatients at UKs Infectious Diseases Clinic, along with eight disease-free volunteers who acted as a control group.

Compared to baseline, the COVID-19 patients had elevated levels of tissue factor, a protein found in blood that initiates the clotting process. Patients also had reduced levels of protein S, an anticoagulant that helps prevent blood clotting.

The researchers concluded that lung inflammation caused by COVID-19 is what leads to a decrease in protein S. Thisinflammation also causes immune and possible endothelial cell activation, which leads to increased tissue factor protein.

What weve learned is that the clotting is not caused by anything systemic. Localized inflammation in the lungs is whats driving this whole process, Wood said. With an increase in tissue factor and a deficiency in protein S, COVID-19 patients get more blood clotting without the ability to shut it down or control it.

The study additionally showed that protein S levels remained low in some patients even after they tested negative for COVID-19, which suggests that blood clotting issues may persist after infection and long-term monitoring of thrombotic risk may be necessary.

Wood says this preliminary data could be a cause for concern. Certain viruses like HIV are linked to a long-term deficiency in protein S, which causes an ongoing risk of thrombosis in patients. It is not yet known if COVID-19 could cause a similar persisting protein S deficiency.

Tissue factor and protein S are good markers to monitor for long-term thrombosis risk and the data suggest that we need to be monitoring these patients because were not seeing these parameters corrected immediately, Wood said.

The research team recently received a grant from UKsCenter for Clinical and Translational Science(CCTS) to begin a longitudinal study to look at these levels in patients over the next year.

This will help answer the question: will this risk remain like it is in the HIV patients or will it go away?

The study was funded in part by anAlliance Grantthrough the College of Medicine as well as UKsCOVID-19 Unified Research Experts (CURE) Alliancethroughthe Vice President for Research and the College of Medicine and the CCTS. It was a product of collaboration between a number of different groups at UK that have been studying COVID-19.

Additional collaborators includeMartha Sim, Meenakshi Banerjee and Hammodah Alfar in the Department of Molecular and Cellular Biochemistry; Melissa Hollifield and Jerry Woodward with Microbiology, Immunology and Molecular Genetics; Xian Li with the Saha Cardiovascular Research Center; Alice Thornton with the Division of Infectious Disease; and Gail Sievert, Marietta Barton-Baxter and Kenneth Campbell with CCTS.

The rest is here:
UK research getting to bottom of COVID clots - ABC 36 News - WTVQ

Read More...

Everything you need to know about DNA (almost) – BBC Focus Magazine

Friday, September 18th, 2020

Deoxyribonucleic acid, or DNA as its usually called, has an appealing mystique. Its in our DNA is now a standard refrain for marketers and individuals trumpeting some essential virtue: honesty, courage, integrity, wholesomeness.

The hype is often misplaced, but undoubtedly DNA is a wondrous molecule with unique, amazing features.

DNA is the only molecule capable of reproducing itself. DNA is present in almost all living cells of all living things. Only DNA, and no other molecule, carries the ability to copy and then pass heritable information to subsequent generations. DNA is, indeed, the essence of life itself.

Despite these apparently magical tricks, DNA follows the ordinary laws of science and nature. Sometimes those rules are not obvious, but a little scientific digging and reliance on robust evidence will ferret them out.

Physically, DNA is a chemical in the form of a twisted, extendable ladder, the iconic double helix. The ladder is composed of rungs and sugar-phosphate siderails.

The rungs consist of a pair of the small chemical bases: adenine, thymine, cytosine, and guanine, abbreviated A, T, C, and G, respectively Crucially, adenine (A) pairs only with thymine (T), and cytosine (C) only pairs with guanine (G). Only the pairs of either A:T or C:G fit as rungs between the two siderails.

The DNA double helix, composed of nucleotide rungs and sugar-phosphate siderails Getty Images

The weight and structure of the DNA ladder naturally twists it into the double helix shape. And the ladder molecule can extend great distances. In a human cell, for example, the number of DNA bases pair rungs in the DNA runs over three billion, measuring over six feet in length.

However, in multicellular organisms like humans, the DNA does not remain as one long strand, but is cut and tightly packed into chromosomes.

Human DNA extracted as a single molecule from a single cell extends to just under two metres long, but is ordinarily segmented and stuffed into 23 pairs of chromosomes in each cell.

All bacteria, plants and animals, including humans, use DNA as the repository of their hereditary information. That is, the recipe to confer every genetic trait, from eye colour to blood type, is carried by segments of DNA stored within each cell of the organism. These DNA segments carrying genetic information are called genes, the root word of genetics.

What differs between human DNA and tomato DNA, or, for that matter, the DNA between two humans, is the precise sequence of DNA base pairs A, T, C, and G. By way of analogy, two different recipes in an English language cookbook may use the same 26 letters to make words but differ in the exact sequence of those same 26 letters, resulting in different recipes.

Read more about genetics:

Although DNA is physically the same double helix composed of long segments of A:T and C:G base pairs in all living things, the exact sequence of those bases varies from one organism to another. It is the order of bases that provides the instructions to produce, say, insulin in human pancreatic cells or photosynthetic enzymes in plants. A plants DNA lacks the base sequences instructions to make insulin, and human DNA lacks instructions for photosynthetic enzymes.

In any organism, such as a given human, the DNA in every cell has the same base sequence as every other living cell in that human.

The difference between a liver cell, and a skin cell is that while both activate (express) those genes required for basic living processes, the liver cell expresses those genes for liver proteins. Other genes remain present, but are not expressed. Meanwhile, skin cells express the genes unique to skin proteins, but liver (and other) genes are silenced.

The language of genetics is the same in all of life. A gene from any cell of any living thing can be copied, transferred and understood by any other living thing to make the same protein.

For example, human insulin is now made by microbes genetically engineered with the human DNA recipe for human insulin. That is, a copy of the human insulin gene is transferred to microbes, and those microbes read the human insulin gene recipe and make insulin, even though the microbes having no blood or blood sugar have no use for insulin. Similarly, most hard cheeses now are made with chymosin (a milk clotting enzyme) generated by genetically modified microbes.

From a scientific perspective, we can confidently state that life began at least once, about 3.5 billion years ago.

A more interesting question, scientifically, is Did life arise more than once?

Answer: unlikely. The evidence is based on DNA being the sole common feature of all living things. More importantly, the language DNA uses to convey information is common to all; the same language is read and understood by all living things. And most importantly, the DNA language is not just the common language used by all species; it is the only language used by any species.

There are no other languages of genetics.

When considering the number of potential languages DNA might have used instead, the fact that all known life forms use the same language of DNA to communicate the same information is compelling evidence that life arose only once.

The fact that all living things use DNA as their physical hardware, and share a single language of DNA as their intellectual software, is evidence that all living things derive from a common ancestor way back when.

Other evidence includes gene homology (a similar DNA base sequence of similar genes in diverse species) and a common synteny (the linear order of adjacent genes in the DNA of a chromosome).

The consensus in the scientific community is that life started once and that evolution provided our current diversity of living things. To be sure, scientists argue strenuously over the mechanics of evolution, and timing, and duration, and other minutia concerning evolutionary processes.

Nevertheless, these arguments do not challenge the scientific consensus: Evolution is real.

Curious humans have always been interested in heredity, pondering how children acquired the features of their parents. But scientists didnt learn that DNA carried the hereditary information until the mid 20th Century. And we didnt know the structure of DNA until 1953. And we didnt know how the genetic information was conveyed within the DNA molecule for some years after that.

More recently, molecular geneticists have learned not only how to read the information carried by a DNA strand, but also how to edit or supplement it. These innovations allow development of a number of commercial products such as the aforementioned insulin and cheese.

DNA is often in the news these days. But it wasnt always so popular. A series of events in the mid-1990s thrust DNA into the spotlight.

Colin Pitchforks murder trial in the UK and O J Simpsons murder trial in the USA sparked public interest in the forensic use of DNA.

Cloning of Dolly the sheep in Scotland raised the spectre of the technical feasibility of cloning humans, a science fiction nightmare.

Then came the appearance on our dinner plates of genetically engineered crops and foods, the fearsome genetically modified organisms, GMOs. All of these high-profile stories were based on the use or perhaps abuse of DNA.

Read more about DNA:

The rocketing popularity of DNA is reflected in the rise of direct-to-consumer DNA testing. For a relatively small fee, several companies will conduct a DNA analysis from the cells in your cheek swab or spit sample. However, these DNA tests are not 100 per cent accurate.

We are all genetically closer to our fellow humans than we might realise. All humans share over 99.9 per cent of their DNA base sequence, so all of the genetic differences between you and your neighbour, or between a Kalahari bushman and a Laplander, are attributable to just 0.1 per cent of the respective DNA.

Even so, the differences, although small, can have dramatic consequences. Your DNA sequence determines your basic blood type (A, B, AB, or O), hair and eye colour, whether your earlobes dangle, and whether you can roll your tongue.

Less trivially, your DNA sequence makes you more (or, if youre lucky, less) susceptible to certain types of cancer, heart disease, blindness, and over 200 other health-related conditions.

The best metaphor illustrating the information storage function of DNA is the encyclopedia of recipes.

Many people cherish their family recipe books handed down from ancestors. The secret, family recipes are sometimes supplemented or annotated, and then shared with children, generation after generation, thus perpetually preserving, albeit with minor changes, the familys culinary tradition.

In principle, the full complement of genetic information in an organism the genome is no different. The genome uses DNA instead of paper to convey the familys precious intellectual property. Our genome is like that multivolume family encyclopedia of recipes. A gene provides instructions and information to the cell, telling the cell to make specific proteins in specific tissues, at specific times, and under specific conditions.

Now, imagine your own family cookbook collection consisting of 23 volumes, with about 20,000 recipes in total, the approximate number of gene recipes in the human genome. We store most of our DNA in 23 pairs of chromosomes, for a total of 46 volumes in each cell. Each chromosome consists of a long DNA chain, with each metaphorical recipe corresponding to a shorter segment of DNA along the chain.

As scientists continue to study and understand DNA, they continue to innovate and devise practical applications.

Police now use DNA to identify long forgotten cold cases. Genealogists use DNA to compile and confirm family trees dating back centuries. Historians use DNA to identify the fragmented remains of lost soldiers, from WWI infantry missing in action at Vimy Ridge to King Richard III under a car park in Leicester.

Doctors use new drugs and medical treatments, including those to combat cancer and the coronavirus, developed from molecular genetic manipulation. And fertility experts help infertile couples have biological children. Understanding DNA and how it functions leads to new technologies while simultaneously enhancing our fascination with the molecule of life.

Still have questions? More on DNA and genetics:

Alan McHughens book, DNA Demystified: Unravelling the Double Helix, is out now (19.99, Oxford University Press).

Visit link:
Everything you need to know about DNA (almost) - BBC Focus Magazine

Read More...

Postdoctoral studies on the molecular mechanisms that regulate aging – Nature.com

Friday, September 18th, 2020

The Department of Biosciences and Nutrition performs research and education in several areas of medical science including aging, molecular endocrinology, cancer biology, functional genomics, systems biology, epigenetics, structural biochemistry, bioorganic chemistry, cellular virology, and nutrition. It offers an excellent international research and working environment, including around 250 scientists, students, administrative and technical personnel. The Department resides in the new biomedical research building Neo, aimed at being a creative and open environment that enables meetings, synergies, and exploration of areas of mutual interest across disciplines.

Do you want to contribute to top quality medical research?

Aging is one of the main risk factors for morbidity and mortality. Thus, a better understanding of the mechanisms that regulate this process is highly desirable. One of our efforts focuses on arguably the most important aging regulator known to date, the transcription factor DAF-16/FOXO. It resides downstream of the nutrient-sensing insulin/IGF signaling pathway and in response to low nutrients activates gene expression programs that slow down the aging process. DAF-16/FOXO depends on a diverse range of binding partners and regulators to fulfill its role, and we are studying their functions by diverse biochemical, genetic, and cytological techniques. (See Lin et al., Nature Communications 2018, or Sen et al., Nature Communications 2020, for examples of such work from our lab.)

Your mission

We are looking for a Postdoc to join our research group, the lab of Christian Riedel. Focus of this position is to explore a new binding partner of DAF-16/FOXO which we found to be required for DAF-16/FOXO to promote longevity in response to low nutrient signals. This work is conducted both in the model organism C. elegans and in human cells. You will synergize with aging biologists and bioinformaticians from the Riedel lab and be part of a larger aging-focused research environment at our department, which also contains the labs of Martin Berg and Maria Eriksson.

We are looking for a talented and highly motivated scientist with a doctoral degree and strong background in Molecular Biology, Cell Biology, Genetics, and/or Biochemistry. Good expertise in either C. elegans methods or in mammalian cell culture techniques is desired. Also, a background in the biology of aging is appreciated, even though it is not essential.

Applicants are expected to work independently but as part of an enthusiastic team and to be proficient in English. They are expected to play a leading role in the design and execution of their experiments as well as the analysis and the presentation/publication of the resulting data. Before and while being in the lab, the applicant will be encouraged to apply for competitive national and international postdoctoral fellowships and career grants and will receive support in those endeavors.

This position will be financed by a postdoc scholarship paid out by Karolinska Institutet.

Scholarships for postdoctoral qualification can be established for foreign researchers who place their qualifications in Sweden. The purpose of scholarships for postdoctoral qualification is to promote internationalization and contribute to research qualification after a doctorate or equivalent.A scholarship for carrying out postdoctoral research can be granted for a maximum of two years within a four year period following the receipt of a doctoral degree or equivalent.To be eligible for a postdoctoral scholarship, the person must have obtained a doctorate or a foreign degree deemed to be equivalent to a doctorate. Applicants who have not completed a doctorate at the end of the application period may also apply, provided that all requirements for a completed degree are met before the (intended) start date of the post doctoral education.

The head of the department determines whether their previous training and scholarly qualifications correspond to a Swedish doctorate or higher.

What do we offer?

A creative and inspiring environment full of expertise and curiosity. Karolinska Institutet is one of the worlds leading medical universities. Our vision is to pursue the development of knowledge about life and to promote a better health for all. At Karolinska Institutet, we conduct successful medical research and hold the largest range of medical education in Sweden.

Location: Department of Biosciences and Nutrition, Neo Building, Flemingsberg

Links: https://ki.se/en/bionut/department-of-biosciences-and-nutrition https://ki.se/en/bionut/christian-riedel-group http://riedellab.org/

The amount is tax free and it is set for twelve months at a time, paid out on a six months basis. In exceptional cases, shorter periods may be acceptable.

An application must contain the following documents in English:

You are welcome to apply at the latest by 16 October 2020.

The application has to be submitted through the Varbi recruitment system.

View post:
Postdoctoral studies on the molecular mechanisms that regulate aging - Nature.com

Read More...

The Undark Interview: A Conversation with Rita Colwell – Undark Magazine

Friday, September 18th, 2020

Rita Colwell is a pioneering microbiologist whose work on cholera helped illuminate the interplay between the environment and public health. She was also the first woman to serve as director of the National Science Foundation, and is currently a Distinguished University Professor at both the University of Maryland and Johns Hopkins Universitys Bloomberg School of Public Health.

In her half-century-plus in the sciences, Colwell has also seen very clearly the array of obstacles confronted by women as they try to navigate a traditionally male world. (When she applied for a graduate fellowship in bacteriology, she says was told, We dont waste fellowships on women.)

A Lab of Ones Own: One Womans Personal Journey Through Sexism in Science, by Rita Colwell and Sharon Bertsch McGrayne (Simon & Schuster, 288 pages).

Colwells new book, A Lab of Ones Own, co-authored with writer Sharon Bertsch McGrayne, documents much of what she has seen and heard over the years, from sexual harassment to the invisible structural obstacles placed in the way of women working in the sciences. (The books subtitle is One Womans Personal Journey Through Sexism in Science.)

Not long ago, women were discouraged from studying science at all; those who did pursue such studies were seen as oddities. Later, when the numbers of women earning science degrees began to rise, they found themselves receiving less funding than their male colleagues, and less likely to land a position as a professor or a lab director. (It wasnt that long ago, Colwell recalls, when a grant application could be turned down because a man on the granting committee simply didnt like women scientists.) But Colwell also found allies along the way, and her book is something of a celebration of what can be achieved when science strives for inclusivity.

The following interview has been edited for length and clarity.

UNDARK: Though sexism has a long history, you write that the 1950s and 60s saw unprecedented levels of sexism in the sciences. What was going on at that time?

Rita Colwell: The attitude was, a woman worked in the home period. A woman couldnt even get a credit card in her own name; she had to have her husband, or her father, vouch for her. In general, the understanding was, if you were [a woman] interested in science, that was peculiar. It wasnt unusual for women to go to college but most did not go from there into any kind of work, unless it was nursing or teaching. It was a very limiting time, for women. A lot of this was unspoken; it was just sort of assumed.

UD: Regarding graduate education, you say that women were simply seen as not worth investing in. What does that mean?

RC: The expectation was that you would get married and have children. If you werent there, with your children, you were seen as a bad mother. You went to college to find a husband; that was the expectation.

UD: You point out that not only could one face obstacles for being a woman Ph.D. student, you could face a backlash if you supervised too many women Ph.D. students. What was that about?

RC: The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest. Having women students would mark you as not serious; your students were just going to get married, and youre just wasting all this time.

UD: As you say, a lot of this was unspoken but eventually there was solid data to quantify this discrimination. How did that come about?

RC: It was in the 90s that Nancy Hopkins at MIT carried out her now-famous experiment: She measured the labs, and discovered that the men had almost twice as much space; they also got the bulk of the research money. More women were entering these careers [in the sciences], but men got most of the funding and most of the space.

Later, Jo Handelsman did the experiment where they sent identical letters to male researchers [from recent graduates applying to be a lab manager], the only difference was that some were signed John and others were signed Jennifer. The question was, would you hire this person, and what would you pay them? Far fewer said they would hire the woman; and the salary they were prepared to offer was much, much lower.

But Id like to emphasize one thing: Once I was able to break through, at each stage of my career, there was tremendous support. My father was very education-minded; it didnt matter if you were a girl or a boy; everyone went to school. My husband, a physicist, was a fantastic supporter; we were married for 62 very happy years. And my Ph.D. supervisor, John Liston, was absolutely the best. He was a newcomer to the University of Washington, starting a new program in marine microbiology so I ended up being the first graduate student with a Ph.D. in marine microbiology, possibly in the whole United States.

The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest.

UD: Youre known for your groundbreaking work on cholera, but it was also fascinating to read about your work investigating the 2001 anthrax attacks, in which a number of politicians and journalists were mailed packages containing the deadly substance in the weeks following the 9/11 attacks. How did you end up on the front lines of that investigation?

RC: I was appointed [as director of the National Science Foundation] by Bill Clinton, and I served two years under Clinton and four under George W. Bush. In October or November [of 2001], we heard about anthrax attacks. I remember saying, Weve got to sequence that bacterium, or well never know who did it.

I had been working on an advisory board for the CIA, so I was able to call on some colleagues, and we formed an inter-agency group. We decided not to make the group official, so that we could keep it a secret. And we worked for five years on this classified project. And using molecular genetics, we tracked down the source. Now, well never know whether the perpetrator was in fact Bruce Ivins, and if he worked alone, or with others. [Ivins died in 2008.] He was an anthrax microbiologist, and the source turned out to be in his lab.

UD: You were using a computer in the late 1950s, long before they became ubiquitous in the life sciences. Did you have a sense that computers would eventually impact every branch of science?

RC: At the University of Washington, I wrote a computer program the first in the country, for bacteriology using the old IBM 650, which has less power than the chip in your microwave oven. When I was working with that computer, I had to program it, and I didnt know diddly. But in my husbands lab, there was a postdoc named George Constabaris, who taught me. And there was another chap who was using the IBM to do pipe-fitting for the ships in Seattle harbor. He was programming how to cut and fit pipe most efficiently.

So it was clear to me that this was an amazing tool. I used the computer for taxonomic purposes, for identification which now everybody does. Its amusing I used to give talks about species of bacteria, and people would yawn. But now the hotshots in Silicon Valley know the differences between different kinds of bacteria. It was clear to me that we had to have massive computation [in the sciences]. I was able to get into the NSF budget, over my term, $2 billion, for computation, for universities to start building the internet railway, so to speak.

UD: So much has changed in science, and in the culture of science, over your career. Today, are you optimistic or at least, more optimistic?

RC: I would say its cautious optimism. I dont know whats going to happen in the next administration; it could be a disaster for women. I strongly encourage girls to go into science. I abhor the assumption that girls cant do math; its absurd. Or that if youre African American you cant do math or you cant do science its crazy. Theres still sexism, which ranges from the criminal to the clueless. Like when someone comments to a woman scientist as shes going up to the podium to give a talk, that she looks attractive. Thats the last thing you want to hear. You want to hear Thats a great idea, or Can we collaborate on the next stage of this experiment?

Read the original:
The Undark Interview: A Conversation with Rita Colwell - Undark Magazine

Read More...

Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the ‘Needle in the Haystack’ Problem of Molecular Biology – Bio-IT World

Friday, September 18th, 2020

Patented CRISPRclean Technology is a Foundational Tool that Improves the Performance of Next-Generation Sequencing and Other Molecular Workflows by Increasing Sensitivity, Reducing Costs and Enabling Novel Discovery

CARLSBAD, CA, UNITED STATES - Sep 17, 2020 - Jumpcode Genomics - a genome technology company founded by industry veterans in 2016 focused on improving the understanding of human disease - today exited stealth mode and announced the commercial launch of its CRISPRclean technology. Initially available via three kits, CRISPRclean unlocks the power of next generation sequencing (NGS) by improving sensitivity, reducing costs and simplifying workflows. The company also announced that it has strengthened its leadership team with the addition of Yaron Hakak, Ph.D., as CEO. In addition, the company has added new advisors, including Dr. Stanley Nelson, vice chairman of Human Genetics at UCLA as consulting chief scientist, and Gary Schroth, Ph.D., vice president and distinguished scientist at Illumina, as a member of the companys scientific advisory board.

CRISPRclean technology is based on the in-vitro utilization of the CRISPR/Cas system to cleave and physically remove nucleic acid sequences pre- or post-NGS library preparation. This enables researchers to remove overabundant and uninformative sequences to allow discovery and detection of molecules previously undetectable (the needles). Like polymerase chain reaction (PCR), the technology broadly applies to many molecular biology techniques, particularly sequencing technologies.

Initial research applications focus on ribosomal RNA depletion, single cell analysis and repeat removal for whole genome sequencing. Additionally, Jumpcode Genomics is pursuing clinical applications, including the removal of human host molecules for a universal pathogen test and depletion of wild type alleles for somatic mutation detection in oncology. The technology seamlessly integrates into existing workflows and is agnostic to library preparation methods and sequencing platforms.

We aim to revolutionize the practice of molecular biology with our technology and to drive better results for researchers today and ultimately patients tomorrow, said Dr. Hakak, CEO of Jumpcode Genomics. When researchers perform NGS on biological samples, most molecules sequenced are uninformative, which results in a needle in a haystack problem. CRISPRclean solves this problem by simply removing the haystack.

The expansion of the leadership team and scientific advisory board enables Jumpcode Genomics to commercialize its technology and strengthen direct access to thought leaders in the scientific community.

About Jumpcode Genomics: Founded in 2016, Jumpcode Genomics aims to improve the understanding of human biology and the contribution to disease. The companys proprietary CRISPRclean technology utilizes the CRISPR/Cas system to deplete unwanted nucleic acid molecules from sequencing libraries. The process fits seamlessly within standard next generation sequencing workflows and works with most commercially available library preparation solutions. For more information, please visit: http://www.jumpcodegenomics.com

View post:
Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the 'Needle in the Haystack' Problem of Molecular Biology - Bio-IT World

Read More...

NIH Funds Research into Differences in Glioblastoma between Males and Females – Health Essentials from Cleveland Clinic

Friday, September 18th, 2020

A team led by researchers from Case Western Reserve University School of Medicine and Cleveland Clinics Lerner Research Institute has secured $10.4 million over five years from the National Institutes of Health/National Cancer Institute to explore at the molecular level the differences in glioblastoma between males and females.

The researchers will delve into the genetics, epigenetics and cell biology of glioblastoma the most common and deadliest brain tumor in adults to better understand the physiologic processes which may lead to more personalized therapies.

The researchers have previously published research showing significant differences between the sexes in glioblastoma incidence, survival and some key molecular pathways. They found that glioblastoma is 60 percent higher in males than in females. In addition, females have a significant survival advantage over males with a median improved survival rate of up to 10 months. However, while these sex differences are understood, they are not yet considered when treating glioblastoma.

The research team is led by co-principal investigators Justin Lathia, Ph.D., of Cleveland Clinics Lerner Research Institute, and Jill Barnholtz-Sloan, Ph.D., of Case Western Reserve University School of Medicine. The team also includes colleagues from Penn State College of Medicine, Washington University School of Medicine in St. Louis, and the Translational Genomics Research Institute (TGen).

Glioblastomas are rare about 3.5-4 per 100,000 in the United States from 2012-16, the most recent data available from the Central Brain Tumor Registry of the United States (CBTRUS). Despite available treatments, glioblastomas have devastating consequences for patients. The median survival time is 12 to 14 months, and only about 5% of patients survive more than five years.

We have the molecular profiling technology and the computing and analytical strength to lead in this effort to better understand the role of sex differences in cancer, particularly for glioblastoma, said Barnholtz-Sloan, the Sally S. Morley Designated Professor in Brain Tumor Research and associate director of Data Sciences at the Case Comprehensive Cancer Center, Case Western Reserve School of Medicine. This next phase of research relies on vast, varied and complex datasets in animals and humans and promises to be a game-changer in how we understand the role of sex in tumor formation and disease outcomes. This comprehensive approach has applications to all forms of cancer, as well as other diseases.

Sex differences are inherent drivers of glioblastoma incidence and survival, and we are taking a multidimensional approach to uncover a better understanding of this differentiation, said Lathia, vice chair of the Department of Cardiovascular and Metabolic Sciences and co-director of the Brain Tumor Research & Therapeutic Development Center of Excellence at Lerner Research Institute, and co-leader of the Molecular Oncology Program at the Case Comprehensive Cancer Center. We are incorporating data from tumor cells and their surrounding micro-environment, as well as genetic programs responsible for tumor growth, and underlying epigenetic differences that may be responsible for sex differences. We aim to gain a better understanding of how these variables interrelate to better understand disease mechanism, which in turn defines better diagnostics and more personalized therapies for patients.

The multi-disciplinary project involves established investigators with complementary expertise and a strong collaborative history. Along with Lathia and Barnholtz-Sloan, participating institutions and their PIs include:

Three related research projects, undertaken by this collaborative team, will delve into the basic biology and cellular mechanisms that drive sex differences in glioblastoma formation and progression. These related research projects will inform, synergize and depend on each other. Findings from the labs based on their animal models will then be queried against data from human clinical samples across multiple institutions. The vast amount of data generated from these studies requires robust data management and sophisticated data analysis for a comprehensive view of sex differences across these diverse but related inquiries.

Comprehensive findings will inform future clinical research design, the search for targets for new therapeutics, or the use of existing therapeutics that may be applied differently depending on a patients sex.

This grant was made by the NIHs National Cancer Institute. Grant number: 1P01CA245705.

Cleveland Clinic: Alicia Reale, 216-408-7444, Realeca@ccf.org

Case Western Reserve: Bill Lubinger, 216-368-4443, william.lubinger@case.edu

The rest is here:
NIH Funds Research into Differences in Glioblastoma between Males and Females - Health Essentials from Cleveland Clinic

Read More...

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for…

Friday, September 18th, 2020

Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results

Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical Practice

VIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen), announced today that scientists at its subsidiary Ares Genetics GmbH (Vienna, Austria; Ares Genetics), in collaboration with researchers from the Johns Hopkins University School of Medicine, have published a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.

P. aeruginosa is listed by the World Health Organization as critical priority pathogen. To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014. While pre-clinical investigations indicated ceftolozane-tazobactam activity against approximately 85%-95% of U.S. and Canadian carbapenem-non-susceptible P. aeruginosa isolates, soon after the clinical introduction of ceftolozane-tazobactam, reports of resistance during therapy emerged.

The study published in Clinical Infectious Diseases sought to understand mechanisms of resistance leading to ceftolozane-tazobactam resistance, the frequency of cross-resistance between ceftolozane-tazobactam and other novel beta-lactam beta-lactamase inhibitor combinations and identify modifiable risk factors that may slow or prevent the acquisition of ceftolozane-tazobactam resistance. Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam. Mutations identified in ceftolozane-tazobactam resistant isolates involved, amongst others, AmpC, a known binding site for ceftolozane, PBP3, the target of ceftolozane, and DNA polymerase. The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.

The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing. Earlier this year, Dr. Patricia Simner of Johns Hopkins Medicine and Ares Genetics presented results from a study assessing the potential of long-read sequencing to predict antimicrobial susceptibility results at the online ASM Microbe 2020 meeting.

Dr. Andreas Posch, CEO Ares Genetics and co-author of both studies, commented, While we have already shown that NGS allows for CLIA-compliant identification of bacterial pathogens and antimicrobial resistance markers as well as accurate prediction of phenotypic resistance in previous publications, the present studies further underline the diagnostic value of NGS as well as the need for rapid antimicrobial resistance testing and improving antibiotic treatment regiments. I am particularly excited about our joint work on using long-read sequencing technology for phenotype prediction as this technology could potentially allow for molecular antibiotic susceptibility testing directly from native patient samples in just a few hours.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Story continues

For more information, please visit http://www.opgen.com.

Forward-Looking Statements by OpGen

This press release includes statements regarding studies and publications of OpGens subsidiary Ares Genetics GmbH. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:Oliver SchachtCEOInvestorRelations@opgen.com

Press Contact:Matthew BretziusFischTank Marketing and PRmatt@fischtankpr.com

Investor Contact:Megan PaulEdison Groupmpaul@edisongroup.com

See the article here:
Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for...

Read More...

Ancient DNA is revealing the genetic landscape of people who first settled East Asia – The Conversation US

Friday, September 18th, 2020

The very first human beings originally emerged in Africa before spreading across Eurasia about 60,000 years ago. After that, the story of humankind heads down many different paths, some more well-studied than others.

Eastern regions of Eurasia are home to approximately 2.3 billion people today roughly 30% of the worlds population. Archaeologists know from fossils and artifacts that modern humans have occupied Southeast Asia for 60,000 years and East Asia for 40,000 years.

But theres a lot left to untangle. Who were the people who first came to these regions and eventually developed agriculture? Where did different populations come from? Which groups ended up predominant and which died out?

Ancient DNA is helping to answer some of these questions. By sequencing the genomes of people who lived many millennia ago, scientists like meare starting to fill in the picture of how Asia was populated.

In 2016, I joined Dr. Qiaomei Fus Molecular Paleontology Lab at the Institute of Vertebrate Paleontology and Paleoanthropology, Chinese Academy of Sciences in Beijing. Our challenge: Resolve the history of humans in East Asia, with the help of collaborators who were long dead ancient humans who lived up to tens of thousands of years ago in the region.

Members of the lab extracted and sequenced ancient DNA using human remains from archaeological sites. Then Dr. Fu and I used computational genomic tools to assess how their DNA related to that of previously sequenced ancient and present-day humans.

One of our sequences came from ancient DNA extracted from the leg bones of the Tianyuan Man, a 40,000-year-old individual discovered near a famous paleoanthropological site in western Beijing. One of the earliest modern humans found in East Asia, his genetic sequence marks him as an early ancestor of todays Asians and Native Americans. That he lived where Chinas current capital stands indicates that the ancestors of todays Asians began placing roots in East Asia as early as 40,000 years ago.

Farther south, two 8,000- to 4,000-year-old Southeast Asian hunter-gatherers from Laos and Malaysia associated with the Habnhian culture have DNA that, like the Tianyuan Man, shows theyre early ancestors of Asians and Native Americans. These two came from a completely different lineage than the Tianyuan Man, which suggested that many genetically distinct populations occupied Asia in the past.

But no humans today share the same genetic makeup as either Habnhians or the Tianyuan Man, in both East and Southeast Asia. Why did ancestries that persisted for so long vanish from the gene pool of people alive now? Ancient farmers carry the key to that answer.

Based on plant remains found at archaeological sites, scientists know that people domesticated millet in northern Chinas Yellow River region about 10,000 years ago. Around the same time, people in southern Chinas Yangtze River region domesticated rice.

Unlike in Europe, plant domestication began locally and was not introduced from elsewhere. The process took thousands of years, and societies in East Asia grew increasingly complex, with the rise of the first dynasties around 4,000 years ago.

Thats also when rice cultivation appears to have spread from its origins to areas farther south, including lands that are todays Southeast Asian countries. DNA helps tell the story. When rice farmers from southern China expanded southward, they introduced not only their farming technology but also their genetics to local populations of Southeast Asian hunter-gatherers.

The overpowering influx of their DNA ended up swamping the local gene pool. Today, little trace of hunter-gatherer ancestry remains in the genes of people who live in Southeast Asia.

Farther north, a similar story played out. Ancient Siberian hunter-gatherers show little relationship with East Asians today, but later Siberian farmers are closely related to todays East Asians. Farmers from northern China moved northward into Siberia bringing their DNA with them, leading to a sharp decrease in prevalence of the previous local hunter-gatherer ancestry.

Genetically speaking, todays East Asians are not very different from each other. A lot of DNA is needed to start genetically distinguishing between people with different cultural histories.

What surprised Dr. Fu and me was how different the DNA of various ancient populations were in China. We and others found shared DNA across the Yellow River region, a place important to the development of Chinese civilization. This shared DNA represents a northern East Asian ancestry, distinct from a southern East Asian ancestry we found in coastal southern China.

When we analyzed the DNA of people who lived in coastal southern China 9,000-8,500 years ago, we realized that already by then much of China shared a common heritage. Because their archaeology and morphology was different from that of the Yellow River farmers, we had thought these coastal people might come from a lineage not closely related to those first agricultural East Asians. Maybe this groups ancestry would be similar to the Tianyuan Man or Habnhians.

But instead, every person we sampled was closely related to present-day East Asians. That means that by 9,000 years ago, DNA common to all present-day East Asians was widespread across China.

Todays northern and southern Chinese populations share more in common with ancient Yellow River populations than with ancient coastal southern Chinese. Thus, early Yellow River farmers migrated both north and south, contributing to the gene pool of humans across East and Southeast Asia.

The coastal southern Chinese ancestry did not vanish, though. It persisted in small amounts and did increase in northern Chinas Yellow River region over time. The influence of ancient southern East Asians is low on the mainland, but they had a huge impact elsewhere. On islands spanning from the Taiwan Strait to Polynesia live the Austronesians, best known for their seafaring. They possess the highest amount of southern East Asian ancestry today, highlighting their ancestrys roots in coastal southern China.

Other emerging genetic patterns show connections between Tibetans and ancient individuals from Mongolia and northern China, raising questions about the peopling of the Tibetan Plateau.

Ancient DNA reveals rapid shifts in ancestry over the last 10,000 years across Asia, likely due to migration and cultural exchange. Until more ancient human DNA is retrieved, scientists can only speculate as to exactly who, genetically speaking, lived in East Asia prior to that.

[Understand new developments in science, health and technology, each week. Subscribe to The Conversations science newsletter.]

See the article here:
Ancient DNA is revealing the genetic landscape of people who first settled East Asia - The Conversation US

Read More...

Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis – The Daily Chronicle

Friday, September 18th, 2020

Data Bridge Market Research has recently published the Global research Report Titled Cardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market. The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Cardiovascular genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4.01 billion by 2027 growing at a CAGR of 13.40% in the above-mentioned forecast period. An extensive array of employment of genetic experimentation in inherent disorders and oncology will prove advantageous for genetic testing business germination in the coming years.

FREE Sample Copy of Research Report Click Here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&kA

The Global Cardiovascular Genetic Testing Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Top Key Vendors Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast to 2026

Why choose us:

A complete value chain of the global Cardiovascular Genetic Testing market is presented in the research report. It is associated with the review of the downstream and upstream components of the Cardiovascular Genetic Testing Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Cardiovascular Genetic Testing market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&KA

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

For More Information or Query or Customization Before Buying, Click Here: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&KA

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA, or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Read more here:
Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis - The Daily Chronicle

Read More...

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies | Antibodies | News Channels – PipelineReview.com

Friday, September 18th, 2020

DetailsCategory: AntibodiesPublished on Friday, 18 September 2020 10:19Hits: 173

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments

INDIANAPOLIS, IN and THOUSAND OAKS, CA, USA I September 17, 2020 I Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies. Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination. Through this collaboration, the two companies will have the ability to quickly scale up production and serve many more patients around the world should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval.

"Based on our initial clinical studies, we believe that virus neutralizing antibodies, including LY-CoV-555, could play an important role in the fight against COVID-19," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "Increasing the manufacturing capacity for our neutralizing antibodies through this collaboration with Amgen is a crucial next step, and together we hope to be able to produce many millions of doses even next year."

"We are impressed with Lilly's data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for COVID-19," said David M. Reese, M.D., executive vice president of research and development at Amgen. Esteban Santos, executive vice president of Operations at Amgen, added "we are proud to partner with Lilly and leverage our deep technical expertise in antibody development and, in particular, our strong capabilities in the scale up and manufacturing of complex biologics. This is yet another example of the ways our industry is closely collaborating to combat this devastating disease and help patients around the world access new therapies."

About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/news. C-LLY

SOURCE: Eli Lilly

Original post:
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies | Antibodies | News Channels - PipelineReview.com

Read More...

Page 9«..891011..2030..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick